News

Patients with severe or progressive zonulopathy are at risk for late postoperative subluxation or dislocation of a capsular tension ring-IOL-capsular bag complex, which occurred about 6 years after implantation.

Results from 2 years of follow-up in a study of presbyopia correction with femtosecond laser intrastromal correction show continued safety, refractive stability, and maintenance of improvements in near visual acuity.

Based on the fact that extraordinary customer service can be a game changer to help position your practice for success in this unstable economy, this article builds from last month's piece on customer service.

Advocates of glaucoma research and education are banding together to present Glaucoma 360?, three days of activities all geared toward increasing awareness of research, treating patients, and finding a cure for the nation's second-leading cause of preventable blindness.

With the Office of Inspector General's heightened awareness of coding and documentation errors, physicians should be aware of some specific areas to check and double-check in their daily routine of documentation.

As results from the FDA IDE clinical trial are awaited, analyses of data from patients receiving earlier versions of an investigational presbyopia-correcting intracorneal inlay show that its efficacy for improving near vision remains stable for at least 3 years.

Bausch + Lomb and Technolas Perfect Vision hope the new femtosecond laser platform unveiled last month at the European Society of Cataract and Refractive Surgeons meeting will replace existing femtosecond laser systems.

European surgeons have access to a wide and expanding range of premium IOLs for implantation after cataract surgery/refractive lens exchange as well as several phakic IOLs.

ARVO's Web seminars are an opportunity to acquire the best practices and practical tools from experienced professionals without leaving one's office or home.

Grafting a thicker amniotic membrane onto the ocular surface may be a promising solution for patients who experience graft failure or require ocular surface reconstruction after penetrating keratoplasty.

In a retrospective chart review that compared three of the most current phacoemulsification technologies for their performance and outcomes during cataract surgery and day 1 after surgery, the Infiniti OZIL-IP outperformed the WhiteStar Signature Ellipsis-FX and the Stellaris System with respect to less phaco needle time, increased followability and stability, less chatter, and less change in corneal pachymetry after surgery that resulted in better day 1 visual outcomes.

Implantation of a toric IOL in eyes with low pre-existing cylinder has benefit for significantly reducing postoperative astigmatism, but surgeons should be mindful of the importance of minimizing surgically induced astigmatism when using a low-cylinder power toric IOL.

Myopic LASIK using a 400-Hz excimer laser is safe, effective, and predictable whether done with a wavefront-guided or wavefront-optimized technique.

Results of a prospective, randomized, patient-masked clinical trial evaluating three presbyopia-correcting IOLs show predictable refractive outcomes were achieved with all three technologies, but indicate there are some differences between the IOLs in visual performance, said Robert E.T. Ang, MD, Asian Eye Institute, Makati City, Philippines.

The European Commission (EC) has granted orphan drug status for an immunosuppressant drug (Sirolimus, Santen Inc.) for the treatment of chronic non?infectious uveitis. The designation follows a positive opinion from the Committee for Orphan Medicinal Products within the European Medicines Agency in June.

The Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through payment status and established a billing code for a telescope implant (Implantable Miniature Telescope [IMT] by Dr. Isaac Lipshitz, VisionCare Ophthalmic Technologies, Inc.) under the Hospital Outpatient Prospective Payment System. The new pass-through code, C1840, is effective October 1. It will enable outpatient facilities to obtain reimbursement for the telescope implant for covered procedures.

The Glaucoma Research Foundation (GRF) will present Glaucoma 360, a three-day series of events offering a ?full-compass view? of the cure, catalysts, and care of glaucoma, Feb. 2 to 4, 2012, at the Palace Hotel in San Francisco.